Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
Лечение аспергиллёза: клинические рекомендации Общества инфекционных заболеваний Америки
2008-01-04
SCID: 54.1/mwmed5np
Discuss with AI
Aspergillosis treatment guidelinesInfectious Diseases Society of America (IDSA)hematopoietic stem cell transplantation (HSCT)immunocompromised patientslung transplantation
Figures from the paper
Abstract (AI)
Aspergillus species have emerged as an important cause of life-threatening infections in immunocompromised patients. This expanding population is composed of patients with prolonged neutropenia, advanced HIV infection, and inherited immunodeficiency and patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and/or lung transplantation. This document constitutes the guidelines of the Infectious Diseases Society of America for treatment of aspergillosis and replaces the practice guidelines for Aspergillus published in 2000 The objective of these
Key Findings
1
Aspergillus species are an important cause of life-threatening infections in immunocompromised patients.
2
High-risk populations include patients with prolonged neutropenia, advanced HIV, inherited immunodeficiency, allogeneic HSCT recipients, and lung transplant recipients.
3
These guidelines update and replace the Infectious Diseases Society of America’s 2000 practice guidelines for treatment of aspergillosis.
Research Object
Treatment of aspergillosis in immunocompromised patients (including those with prolonged neutropenia, advanced HIV, inherited immunodeficiency, allogeneic HSCT and lung transplantation)
Research Subject
Clinical practice guideline recommendations for the treatment of aspergillosis (therapeutic strategies, indications, and management in the specified immunocompromised populations)
Publication Details
Publication Date
2008-01-04
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest